↓ Skip to main content

Dove Medical Press

Article Metrics

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Overview of attention for article published in Biologics: Targets & Therapy, December 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 223)
  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
93 Mendeley
Title
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
Published in
Biologics: Targets & Therapy, December 2010
DOI 10.2147/btt.s5775
Pubmed ID
Authors

Tariq Mughal

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 1%
Japan 1 1%
United States 1 1%
Czechia 1 1%
Unknown 89 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 28 30%
Student > Master 13 14%
Student > Postgraduate 8 9%
Researcher 8 9%
Student > Ph. D. Student 7 8%
Other 13 14%
Unknown 16 17%
Readers by discipline Count As %
Medicine and Dentistry 22 24%
Biochemistry, Genetics and Molecular Biology 20 22%
Agricultural and Biological Sciences 10 11%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Chemistry 4 4%
Other 8 9%
Unknown 22 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2019.
All research outputs
#3,416,106
of 17,371,891 outputs
Outputs from Biologics: Targets & Therapy
#35
of 223 outputs
Outputs of similar age
#94,003
of 327,880 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 1 outputs
Altmetric has tracked 17,371,891 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 223 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,880 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them